Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27023-27036

  Tiffen, Jessamy C ^a,b,g   Gunatilake, Dilini ^a,b,g   Gallagher, Stuart J ^a,b,g   Gowrishankar, Kavitha ^a,b,g   Heinemann, Anja ^a,b,g   Cullinane, Carleen ^c   Dutton Regester, Ken ^d   Pupo, Gulietta M ^e   Strbenac, Dario ^a   Yang, Jean Y ^a   Madore, Jason ^f,g   Mann, Graham J ^a,e,g   Hayward, Nicholas K ^d   McArthur, Grant A ^c   Filipp, Fabian V ^h   Hersey, Peter ^a,b,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g MELANOMA INSTITUTE AUSTRALIA   (Australia)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epigenetics; EZH2; H3K27me3; Melanoma; Targeted therapy

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; APOPTOSIS INDUCING FACTOR; APOPTOSIS INDUCING FACTOR MITOCHONDRION ASSOCIATED 1 PROTEIN; CASPASE; GSK 126; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ATF3 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; GSK126; HISTONE; INDOLE DERIVATIVE; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MOLECULARLY TARGETED THERAPY; POLYMERASE CHAIN REACTION; PROTEIN DEPLETION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; TUMOR SUPPRESSOR GENE; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; IC50; METABOLISM; MUTATION; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 3; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENOMICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GENOTYPE; HISTONES; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MELANOMA; MUTATION; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONES; SKIN NEOPLASMS; UP-REGULATION;

EID: 84942751234     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4809     Document Type: Article

References (55)

1. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005; 2:S4-11.
2. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013; 153:38-55. Epub 2013/04/02.
3. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer. 2010; 10:669-82.
4. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469:343-9.
5. Takeshima H, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. Identification of co-existence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis. 2014; 4.
6. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006; 439:871-4.
7. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010; 7:299-313.
8. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A. 2012; 109:2989-94.
9. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinalcenter origin. Nat Genet. 2010; 42:181-5.
10. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 2010; 107:20980-5.
11. Antonysamy S, Condon B, Druzina Z, Bonanno JB, Gheyi T, Zhang F, et al. Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2- SET Domain. PLoS One. 2013; 8:0084147.
12. Wu H, Zeng H, Dong A, Li F, He H, Senisterra G, et al. Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations. PLoS One. 2013; 8:0083737.
13. Tiffen J, Gallagher SJ, Hersey P. EZH2: an emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell Melanoma Res. 2014; 10:12280.
14. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401-4.
15. Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015; 6.
16. Hou P, Liu D, Dong J, Xing M. The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle. 2012; 11:286-95.
17. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol. 2007; 34:597-600. Epub 2007/07/21.
18. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget. 2012; 3:1011-25.
19. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006; 24:268- 73. Epub 2005/12/07.
20. Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC, et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res. 2011; 9:418-29. Epub 2011/03/09.
21. Holling TM, Bergevoet MW, Wilson L, Van Eggermond MC, Schooten E, Steenbergen RD, et al. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol. 2007; 179:5317-25.
22. Yan J, Zhong N, Liu G, Chen K, Liu X, Su L, et al. Usp9xand Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis. 2014; 3:281.
23. Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla- Gokcumen GE, Williams DS, et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 2007; 67:209-17.
24. Zhang J, Bardot E, Ezhkova E. Epigenetic regulation of skin: focus on the Polycomb complex. Cell Mol Life Sci. 2012; 69:2161-72. Epub 2012/02/09.
25. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492:108-12. Epub 2012/10/12.
26. Beaumont K, Mohana-Kumaran N, Haass N. Modeling Melanoma In vitro and In vivo. Healthcare. 2013; 2:27.
27. Barsotti AM, Ryskin M, Zhong W, Zhang WG, Giannakou A, Loreth C, et al. Epigenetic reprogramming by tumorderived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Oncotarget. 2015. Epub 2015/02/12.
28. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005; 19:1294-305.
29. Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, et al. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res. 2012; 18:783-95.
30. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009; 8:1579-88.
31. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9:400-14.
32. Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Molecular and cellular biology. 1998; 18:629-43. Epub 1998/01/07.
33. Choi YH, Lee WH, Park K-Y, Zhang L. p53-independent Induction of p21 (WAF1/CIP1), Reduction of Cyclin B1 and G2/M Arrest by the Isoflavone Genistein in Human Prostate Carcinoma Cells. Japanese Journal of Cancer Research. 2000; 91:164-73.
34. Thompson MR, Xu D, Williams BR. ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med. 2009; 87:1053-60.
35. Lu D, Wolfgang CD, Hai T. Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem. 2006; 281:10473-81.
36. Wang Z, Xu D, Ding HF, Kim J, Zhang J, Hai T, et al. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model. Oncogene. 2014; 22:426.
37. Chhabra R, Dubey R, Saini N. Gene expression profiling indicate role of ER stress in miR-23a~27a~24-2 cluster induced apoptosis in HEK293T cells. RNA Biol. 2011; 8:648-64.
38. Mungrue IN, Pagnon J, Kohannim O, Gargalovic PS, Lusis AJ. CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade. J Immunol. 2009; 182:466-76.
39. Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, et al. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3- only protein NOXA. J Biol Chem. 2011; 286:24882-95.
40. Murakami Y, Hosoi F, Izumi H, Maruyama Y, Ureshino H, Watari K, et al. Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/ Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochemical and Biophysical Research Communications. 2010; 396:376-81.
41. Fang BA, Kovacevic Z, Park KC, Kalinowski DS, Jansson PJ, Lane DJ, et al. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta. 2014; 1:1-19.
42. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z, Richardson DR. The iron chelators Dp44mT and DFO inhibit TGF-ß-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). Journal of Biological Chemistry. 2012; 287:17016-28.
43. Tiwari N, Tiwari Vijay K, Waldmeier L, Balwierz Piotr J, Arnold P, Pachkov M, et al. Sox4 Is a Master Regulator of Epithelial-Mesenchymal Transition by Controlling Ezh2 Expression and Epigenetic Reprogramming. Cancer Cell. 2013; 23:768-83.
44. Menezes ME, Bhatia S, Bhoopathi P, Das SK, Emdad L, Dasgupta S, et al. MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol. 2014; 818:127-53.
45. Zhuo B, Wang R, Yin Y, Zhang H, Ma T, Liu F, et al. Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo. Tumour Biol. 2013; 34:2419-26.
46. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, et al. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther. 2005; 11:724-33.
47. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 1998; 161:2195-200.
48. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 1999; 59:2747-53.
49. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protocols. 2007; 2:1445-57.
50. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998; 72:8463-71.
51. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47.
52. Shi W, Oshlack A, Smyth GK. Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Research. 2010; 38:e204.
53. Johnson DS, Mortazavi A, Myers RM, Wold B. Genomewide mapping of in vivo protein-DNA interactions. Science. 2007; 316:1497-502.
54. Smalley KS, Lioni M, Noma K, Haass NK, Herlyn M. In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opin Drug Discov. 2008; 3:1-10.
55. Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol. 2013; 133:509-17.